| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:11097870 | IVTH | 0.0000001 M | 0.0000001 M | Affects expression of androgen receptor (AR) | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00000001 M | - | No significant effects observed | - | |
| IVTH | 0.00000003 M | - | No significant effects observed | - | |
| IVTH | 0.0000001 M | 0.0000001 M | Cancer phenotype | Endocrine-mediated cancer | |
| PMID:32325588 | IVR | 0.00001 - 0.0001 mg/kg | 0.00001 - 0.0001 mg/kg | Causes inflammation | Immunological endocrine-mediated perturbations |
| IVR | 0.0001 mg/kg | 0.0001 mg/kg | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg | 0.0001 mg/kg | Affects Wnt signaling pathway | Developmental endocrine-mediated perturbations | |
| PMID:32835916 | IVR | 0.25 mg/kg | 0.25 mg/kg | Causes inflammation | Immunological endocrine-mediated perturbations |
| IVR | 0.025 - 0.25 mg/kg | 0.025 - 0.25 mg/kg | Affects cytokine signaling | Immunological endocrine-mediated perturbations | |
| IVR | 0.025 - 0.25 mg/kg | 0.025 - 0.25 mg/kg | Elevated insulin levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.025 - 0.25 mg/kg | 0.025 - 0.25 mg/kg | Elevated glucose levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.25 mg/kg | 0.25 mg/kg | Decreased HDL levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.025 mg/kg | 0.025 mg/kg | Increased triglycerides level | Metabolic endocrine-mediated perturbations | |
| IVR | 0.025 - 0.25 mg/kg | 0.025 - 0.25 mg/kg | Increased LDL levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.025 - 0.25 mg/kg | 0.025 - 0.25 mg/kg | Increased body weights | Metabolic endocrine-mediated perturbations | |
| IVR | 0.025 - 0.25 mg/kg | 0.025 - 0.25 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.025 - 0.25 mg/kg | 0.025 - 0.25 mg/kg | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.025 - 0.25 mg/kg | 0.025 - 0.25 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.025 - 0.25 mg/kg | 0.025 - 0.25 mg/kg | Increased adiposity | Metabolic endocrine-mediated perturbations | |
| IVR | 0.25 mg/kg | 0.25 mg/kg | Altered adipocyte morphology | Metabolic endocrine-mediated perturbations | |
| PMID:34207679 | IVR | 0.0005 - 0.5 mg/kg | 0.0005 - 0.5 mg/kg | Induce behavioral changes | Neurological endocrine-mediated perturbations |
| PMID:35077874 | IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Decrease in T4 levels | Metabolic endocrine-mediated perturbations |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Decrease in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Affects thyroid function | Metabolic endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Induce behavioral changes | Neurological endocrine-mediated perturbations | |
| PMID:35430282 | IVR | 1 - 5 mg/kg | 1 - 5 mg/kg | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| IVR | 1 - 5 mg/kg | 1 - 5 mg/kg | Alterations in number of leydig cells | Reproductive endocrine-mediated perturbations | |
| IVR | 1 - 5 mg/kg | 1 - 5 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 1 - 5 mg/kg | 1 - 5 mg/kg | Decreased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 1 - 5 mg/kg | 1 - 5 mg/kg | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| PMID:35563431 | IVTH | 0.00000002 - 0.0000002 M | 0.00000002 - 0.0000002 M | Reduced insulin levels | Metabolic endocrine-mediated perturbations |
| IVTH | 0.00000001 - 0.0000002 M | 0.00000001 - 0.0000002 M | Affects insulin signaling | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.00000002 - 0.0000002 M | 0.00000002 - 0.0000002 M | Elevated insulin levels | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.00000002 - 0.0000002 M | 0.00000002 - 0.0000002 M | Oxidative stress in pancreatic cells | Metabolic endocrine-mediated perturbations | |
| PMID:35690288 | IVR | 0.001 mg/kg/day | 0.001 mg/kg/day | Affects thyroid function | Metabolic endocrine-mediated perturbations |
| IVR | 0.0002 - 0.001 mg/kg/day | 0.0002 - 0.001 mg/kg/day | Oxidative stress in thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 0.0002 - 0.001 mg/kg/day | 0.0002 - 0.001 mg/kg/day | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| PMID:36638932 | IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Increased LDL levels | Metabolic endocrine-mediated perturbations |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Changes in morphology of adipose tissue | Metabolic endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Induce behavioral changes | Neurological endocrine-mediated perturbations | |
| PMID:36740725 | IVR | 0.00000005 M | 0.00000005 M | Lead to obesity | Metabolic endocrine-mediated perturbations |
| PMID:39032759 | IVR | 0.0001 mg/kg | 0.0001 mg/kg | Causes inflammation | Immunological endocrine-mediated perturbations |
| IVR | 0.0001 mg/kg | 0.0001 mg/kg | Affects survival of live fetus | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg | 0.0001 mg/kg | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg | 0.0001 mg/kg | Increased gonadotropin-releasing hormone (GnRH) levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg | 0.0001 mg/kg | Increased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg | 0.0001 mg/kg | Induce apoptosis of ovarian follicles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg | 0.0001 mg/kg | Changes in ovarian morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg | 0.0001 mg/kg | Affects ovarian follicles population | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg | 0.0001 mg/kg | Affects estrogen signaling | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg | 0.0001 mg/kg | Affects folliculogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg | 0.0001 mg/kg | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg | 0.0001 mg/kg | Alterations in endometrial morphology | Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.